AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

From the quarter under review, a change has been made in respect to the impact of exchange rate fluctuations pertaining to changes in SG&A expenses, which are now included under exchange rate ...

Fellow, the specialty beverage gear company helping elevate everyday rituals into moments that matter, announced today that the Aiden Precision Coffee Maker was named as a winner in Good ...

Analysis of Hawaiian Electric's Q3 performance: a loss of $0.91/share due to wildfire liabilities, settlement agreements, and strategic review of clean energy subsidiary.

Yet, AbbVie’s emraclidine has floundered where Karuna prospered. AbbVie’s phase 2 trials tested emraclidine as a once-daily, oral monotherapy in adults with schizophrenia experiencing an acute ...

EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...